GBA

Gain Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Friday, September 17, 2021 - 1:00pm

BETHESDA, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit and invites investors to participate via webcast and in one-on-one meetings. Please see additional details below:

Key Points: 
  • Please contact your representative at Oppenheimer & Co. to schedule a virtual one-on-one meeting with Gain Therapeutics during the respective conference.
  • For more information about the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, please refer to the conference website .
  • Gain Therapeutics, Inc. is positioned at the confluence of technology and healthcare and focused on redefining drug discovery with its SEE-Tx target identification platform.
  • In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc. For periods and at dates prior to the Corporate Reorganization, the consolidated financial statements were prepared based on the historical financial statements of GT Gain Therapeutics SA.

EHang Partners with HELI-EASTERN for Urban Air Mobility Operations in Integrated Airspace in Shenzhen

Wednesday, September 15, 2021 - 3:01pm

The ground-breaking partnership will explore and further implement urban air mobility (UAM) operations in the designated integrated airspace for helicopters and AAVs in Shenzhen, China.

Key Points: 
  • The ground-breaking partnership will explore and further implement urban air mobility (UAM) operations in the designated integrated airspace for helicopters and AAVs in Shenzhen, China.
  • This is an important milestone in implementing EHang's 100 Air Mobility Routes Initiative in the Greater Bay Area.
  • In addition, two units of EHang 216 AAVs showcased trial flights simultaneously and safely in the shared airspace.
  • We will leverage our strengthsin both software and hardware technologies to partner with HELI-EASTERN in continuing to nurture the eco-system for urban air mobility operations."

Vanqua Bio Launches with $85 Million Series B Financing and a Mission to Vanquish Neurodegenerative Diseases

Tuesday, September 14, 2021 - 12:00pm

CHICAGO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Vanqua Bio, a Chicago-based biopharmaceutical company dedicated to discovering and developing next-generation medicines for neurodegenerative diseases, today announced that it closed an $85 million Series B financing round, led by Omega Funds. The syndicate includes Series A investor OrbiMed and new investors Omega Funds, Surveyor Capital (a Citadel company), Avoro Ventures, Casdin Capital, Pontifax, Eli Lilly and Company, Logos Capital, and Osage University Partners. Proceeds from the financing will be used to accelerate the development of the company’s innovative therapeutic programs. The need for effective neurodegenerative therapies is urgent; every day, the lives of thousands of people are changed forever following a diagnosis of Parkinson’s disease (PD), Gaucher disease (GD), Alzheimer’s disease (AD), or amyotrophic lateral sclerosis (ALS).

Key Points: 
  • CHICAGO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Vanqua Bio, a Chicago-based biopharmaceutical company dedicated to discovering and developing next-generation medicines for neurodegenerative diseases, today announced that it closed an $85 million Series B financing round, led by Omega Funds.
  • Vanqua Bio is helping usher in a new era of hope for people living with neurodegenerative disorders.
  • Vanqua Bios Series B financing will advance the companys best-in-class GCase activators into human testing within the next two years, initially focusing on GD and GBA-PD.
  • Co-Founder Dr. Dimitri Krainc , a leading expert on uncovering molecular pathways that contribute to neurodegenerative diseases, chairs Vanqua Bios Scientific Advisory Board.

Government Wakes up to Blockchain & Cryptocurrency

Monday, September 13, 2021 - 2:53pm

Language in this bill suggests that $28 Billion in funding will come from enforcing tax-reporting requirements on cryptocurrency brokers.

Key Points: 
  • Language in this bill suggests that $28 Billion in funding will come from enforcing tax-reporting requirements on cryptocurrency brokers.
  • A cryptocurrency broker is anyone who buys or sells cryptocurrency.
  • This fall, the Government Blockchain Association (GBA) (www.gbaglobal.org) has partnered with a coalition of blockchain associations to present Blockchain & Infrastructure, a two-day hybrid event coupling an educational seminar with a networking reception.
  • As the debate over blockchain and cryptocurrency torches through Congress, one thing is crystal clear: government regulation of this technology is on the table NOW.

Gain Therapeutics to Present at 2021 International Virtual GM1 Community Conference

Thursday, September 9, 2021 - 9:20pm

GM1 Gangliosidosis is a hereditary, progressive disease mostly impacting neurons in the brain and spinal cord, caused by mutations in GLB1.

Key Points: 
  • GM1 Gangliosidosis is a hereditary, progressive disease mostly impacting neurons in the brain and spinal cord, caused by mutations in GLB1.
  • In both diseases, these mutations result in the misfolding and subsequent dysfunction of GLB, which leads to toxic substrate accumulation in organs and tissues.
  • Gain Therapeutics, Inc. is positioned at the confluence of technology and healthcare and focused on redefining drug discovery with its SEE-Tx target identification platform.
  • In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc. For periods and at dates prior to the Corporate Reorganization, the consolidated financial statements were prepared based on the historical financial statements of GT Gain Therapeutics SA.

Sixth Belt and Road Summit draws to successful close

Friday, September 3, 2021 - 4:00am

HONG KONG, Sept 3, 2021 - (ACN Newswire) - The sixth Belt and Road Summit, jointly organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), drew to a successful close yesterday (2 September).

Key Points: 
  • HONG KONG, Sept 3, 2021 - (ACN Newswire) - The sixth Belt and Road Summit, jointly organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), drew to a successful close yesterday (2 September).
  • Under the theme "Driving Growth through Fostering Regional and International Trade", the sixth Belt and Road Summit brought together more than 17,000 participants from about 80 countries and regions.
  • They all came together to discuss the latest developments driven by the Belt and Road Initiative.
  • - Belt and Road Summit website: https://www.beltandroadsummit.hk/en
    - HKTDC Belt and Road Portal: http://beltandroad.hktdc.com
    The Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade.

Gain Therapeutics, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Thursday, September 2, 2021 - 9:05pm

An on-demand corporate presentation will be accessible to conference attendees starting on Monday, September 13th at 7:00 am ET for 90 days after the event.

Key Points: 
  • An on-demand corporate presentation will be accessible to conference attendees starting on Monday, September 13th at 7:00 am ET for 90 days after the event.
  • Eric Richman, Chief Executive Officer and Salvatore Calabrese, Chief Financial Officer, will be scheduling virtual 1x1 meetings and encourage investors to schedule a time during the conference.
  • If you are interested in arranging a one-on-one meeting, please contact your H.C. Wainwright representative.
  • For more information about the 23rd Annual Global Investment Conference, please visit the H.C. Wainwright conference website https://hcwevents.com/annualconference/
    Gain Therapeutics, Inc. is positioned at the confluence of technology and healthcare and focused on redefining drug discovery with its SEE-Tx target identification platform.

The Silverstein Foundation for Parkinson’s with GBA Announces Grant Funding to AcureX Therapeutics

Tuesday, August 31, 2021 - 2:00pm

NEW YORK and SAN CARLOS, Calif., Aug. 31, 2021 (GLOBE NEWSWIRE) -- The Silverstein Foundation for Parkinsons with GBA today announced grant funding to AcureX Therapeutics to support the development of novel, first in class, small molecule drug candidates for the treatment of Parkinsons disease (PD).

Key Points: 
  • NEW YORK and SAN CARLOS, Calif., Aug. 31, 2021 (GLOBE NEWSWIRE) -- The Silverstein Foundation for Parkinsons with GBA today announced grant funding to AcureX Therapeutics to support the development of novel, first in class, small molecule drug candidates for the treatment of Parkinsons disease (PD).
  • We are proud to have the support of The Silverstein Foundation for Parkinsons with GBA.
  • Jonathan Silverstein, founder of The Silverstein Foundation for Parkinsons with GBA, added, The Foundation is committed to supporting the development of innovative therapeutics that leverage genetic insights to treat and reverse the neurodegenerative process in PD.
  • The Silverstein Foundation is a 501(c)(3) non-profit organization focused on investing in cutting-edge therapeutic approaches for the treatment and prevention of Parkinsons disease in glucocerebrosidase (GBA) mutation carriers.

Nouveau Monde Admitted to the Global Battery Alliance – with Focus on Promoting Sustainability and Accountability for the Entire Battery Materials Value Chain

Tuesday, August 31, 2021 - 8:00am

Through this public-private collaboration platform, Nouveau Monde joins battery manufacturers, automakers, technology companies, governments, and international organizations.

Key Points: 
  • Through this public-private collaboration platform, Nouveau Monde joins battery manufacturers, automakers, technology companies, governments, and international organizations.
  • Building upon ten key guiding principles , flagship initiatives, and taskforces, the GBA actively works to advance climate action via the sustainable development of the battery ecosystem.
  • The project is affiliated with the GBA to inform global standards on battery identity and reporting criteria for sustainable and transparent battery production.
  • With low-cost operations and enviable ESG standards, Nouveau Monde aspires to become a strategic supplier to the worlds leading battery and automobile manufacturers, providing high performing and reliable advanced materials while promoting sustainability and supply chain traceability.

Geekvape invests several billion yuan to build an intelligent manufacturing industrial park in China's Greater Bay Area

Saturday, August 28, 2021 - 8:39am

Geekvape plans to build a modern industrial park for intelligent manufacturing over the next two years.

Key Points: 
  • Geekvape plans to build a modern industrial park for intelligent manufacturing over the next two years.
  • With the construction of the park, Geekvape aims to accelerate its transition to high-end intelligent manufacturing with continuous investment in technological innovations and ultimately take the industry to the next level.
  • Through the investment, Geekvape becomes the first company in the industry to build modular intelligent manufacturing facilities and transform traditional manufacturing processes.
  • Geekvape will provide our customers across over 70 countries and regions with better products and services enhanced by intelligent manufacturing and innovative technologies."